SkinBioTherapeutics Faces Share Suspension as Forensic Review Delays Interim Results

SkinBioTherapeutics ( (GB:SBTX) ) has shared an announcement.

SkinBioTherapeutics has delayed publication of its interim results for the six months to 31 December 2025 while an independent forensic review by FRP Advisory into previously disclosed matters continues. As a result, the company expects trading in its AIM-listed shares to be suspended from 1 April 2026 until the investigation concludes and the interim results are released, although it reports a robust cash position of £2.44m and says operations remain on a business-as-usual footing.

The board plans to update shareholders once the review and its own investigation are complete, a process that could affect investor confidence and short-term liquidity given the anticipated trading halt. However, management emphasises that the group’s underlying businesses continue to trade normally, suggesting that the issues under review are centred on governance and reporting rather than immediate operational disruption.

The most recent analyst rating on (GB:SBTX) stock is a Hold with a £9.50 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.

Spark’s Take on SBTX Stock

According to Spark, TipRanks’ AI Analyst, SBTX is a Neutral.

The score is primarily held back by continued losses and negative operating/free cash flows despite strong revenue growth. Technicals add further pressure due to a clear downtrend across major moving averages and bearish momentum indicators, while valuation is difficult to interpret positively given the negative P/E and lack of dividend support.

To see Spark’s full report on SBTX stock, click here.

More about SkinBioTherapeutics

SkinBioTherapeutics is a UK-based life science company focused on skin health, built around its proprietary SkinBiotix platform developed with the University of Manchester. Its main pillars target the skin healthcare market through cosmetic skincare and gut-skin axis food supplements, supported by partnerships, retail distribution, and acquisitions in complementary skincare and cosmetic fields.

Average Trading Volume: 4,562,740

Technical Sentiment Signal: Sell

Current Market Cap: £24.88M

See more insights into SBTX stock on TipRanks’ Stock Analysis page.